Drug Type CRISPR/Cas9 |
Synonyms- |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Cure Rare Disease, Inc.Startup |
Active Organization Cure Rare Disease, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophies | Preclinical | US | Cure Rare Disease, Inc.Startup | 09 Jan 2024 |